Kidney International Reports最新文献

{"title":"Early and Sensitive Detection of Cisplatin-Induced Kidney Injury Using Novel Biomarkers","authors":"Michael Strader ,&nbsp;Gary Friedman ,&nbsp;Xavier Benain ,&nbsp;Nunzio Camerlingo ,&nbsp;Stefan Sultana ,&nbsp;Shiran Shapira ,&nbsp;Nadir Aber ,&nbsp;Patrick T. Murray","doi":"10.1016/j.ekir.2025.01.035","DOIUrl":"10.1016/j.ekir.2025.01.035","url":null,"abstract":"<div><h3>Introduction</h3><div>We evaluated a panel of novel urinary and serum biomarkers (BMs) for early and sensitive detection of cisplatin drug-induced kidney injury (DIKI) in patients with cancer, comparing their diagnostic accuracy with standard BMs (SBMs).</div></div><div><h3>Methods</h3><div>In this prospective exploratory observational study, 105 patients treated with cisplatin (“treated” with &gt; 65 mg/m²/cycle), 20 non-cisplatin treated cancer controls (“nontreated”), and 34 “healthy” controls were enrolled. The treated group’s serum and urine samples were collected predose, after 12 hours, and on days 1, 2, 4, 7, 14, and 21. SBMs and novel BMs (NBMs; 8 urinary, 1 serum) were measured, comparing accuracy, percent changes from baseline (PCFBs), and median time to peak values between treated patients and nontreated cancer controls. Blinded adjudication of the treated group’s BM profiles occurred at 2 stages for DIKI diagnosis.</div></div><div><h3>Results</h3><div>All urinary NBMs had significant PCFBs in the treated group compared with the nontreated cancer control group; most accurately detected cisplatin exposure (area under the receiver operating characteristics [ROC] curve [AUROC] &gt; 0.8). NBMs peaked earlier. In stage 1 adjudication (SBMs) of the treated group, PCFB of urinary NBMs showed no difference between DIKI (<em>n</em> = 24) and no-DIKI (<em>n</em> = 71) groups except for neutrophil gelatinase-associated lipocalin (NGAL) and cystatin C (CYSC). In treated participants, all BMs showed greater PCFBs than control groups, regardless of stage 1 DIKI adjudication. Stage 2 (SBMs and NBMs), DIKI incidence (<em>n</em> = 63) increased by 41%, with most BMs having an AUROC &gt; 0.80 compared with the nontreated cancer control group.</div></div><div><h3>Conclusion</h3><div>NBMs accurately and timely detected cisplatin exposure and identified “sub-clinical” DIKI undetected by standard acute kidney injury (AKI) criteria, highlighting the limitations of current functional BMs in estimating the true DIKI incidence.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1175-1187"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survey on Plasmapheresis Practices in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis: Insights From Two Clinical Case Studies","authors":"Cyril Mousseaux ,&nbsp;Cedric Rafat ,&nbsp;Yosu Luque ,&nbsp;Laurent Mesnard","doi":"10.1016/j.ekir.2025.01.041","DOIUrl":"10.1016/j.ekir.2025.01.041","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1292-1295"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Searching for Fire Amid the Smoke: Will Cannabinoids Prove Useful and Safe for Those With CKD?","authors":"Brendan Smyth ,&nbsp;David Collister","doi":"10.1016/j.ekir.2025.01.031","DOIUrl":"10.1016/j.ekir.2025.01.031","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 988-990"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “WCN25-3808 NAFLD IN ESRD – PREVALENCE OF NAFLD in ESRD PATIENTS AND EVALUATION OF THERAPEUTIC EFFICACY OF TOCOTRIENOL IN TREATMENT OF NAFLD” [Kidney International Reports Volume 10, Issue 2, Supplement, February 2025, Pages S339-S340]","authors":"Georgi Abraham ,&nbsp;Gayatri Veeramani Jayaraman ,&nbsp;Milly Mathew ,&nbsp;Arul Prakash ,&nbsp;Latha Kumaraswamy","doi":"10.1016/j.ekir.2025.01.046","DOIUrl":"10.1016/j.ekir.2025.01.046","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Page 1302"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extrarenal Clinical Features are Reported for Most Genes Implicated in Genetic Kidney Disease","authors":"Benjamin Serrano ,&nbsp;Judy Savige","doi":"10.1016/j.ekir.2025.01.045","DOIUrl":"10.1016/j.ekir.2025.01.045","url":null,"abstract":"<div><h3>Introduction</h3><div>Genetic kidney disease is often suspected based on a family history of the disease or the presence of extrarenal features. This study examined how often a positive family history or syndromic features are found.</div></div><div><h3>Methods</h3><div>A total of 255 genes from the Genomics England “green” lists for congenital anomalies of the kidney and urinary tract (CAKUT) (<em>n</em> = 57), ciliopathies and cystic kidney diseases (<em>n</em> = 90), hematuria (<em>n</em> = 5), renal proteinuria (<em>n</em> = 55), and renal tubulopathies (<em>n</em> = 48) were examined for mode of inheritance and, in the Online Mendelian Inheritance in Man (OMIM), for reported clinical features in different systems (neurological, cardiac, etc.) that would be obvious on a history or physical examination.</div></div><div><h3>Results</h3><div>Autosomal recessive (AR) inheritance was recorded for 148 of the 248 genes (60%) with an OMIM entry. Extrarenal features were associated with 221 genes (89%), including those causing hematuria (5, 100%), renal ciliopathies (86, 97%), CAKUT (52, 91%), renal tubulopathies (41, 85%), and proteinuric renal diseases (37, 76%).The median number of affected systems was 4 (range: 0–10). More extrarenal features were associated with CAKUT (4, 0–10) and the ciliopathies (5, 0–9) than with hematuria (2, 2–5), proteinuria (3, 0–7), and the tubulopathies (3, 0–7) (<em>P</em> &lt; 0.00001). The most commonly-affected systems were growth and musculoskeletal (164, 66%), neurological (147, 59%), and ocular (133, 54%).</div></div><div><h3>Conclusion</h3><div>Extrarenal associations have been reported for most genes affected in genetic kidney disease, and are more common with pediatric-onset conditions with recessive inheritance. However, information is limited for how often extrarenal features are found in any individual.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1196-1204"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized Trial of Lower-Dose Roxadustat Efficacy and Safety in Non–Dialysis-Dependent CKD-Associated Anemia","authors":"Ping Li ,&nbsp;Xuefeng Sun ,&nbsp;Li Zhang ,&nbsp;Hongli Lin ,&nbsp;Niansong Wang ,&nbsp;Yuehong Li ,&nbsp;Sumei Zhao ,&nbsp;Ping Fu ,&nbsp;Hong Cheng ,&nbsp;Zhiyong Guo ,&nbsp;Wanhong Lu ,&nbsp;Yani He ,&nbsp;Fengmin Shao ,&nbsp;Qiang He ,&nbsp;Yiqing Wu ,&nbsp;Cuihua Huang ,&nbsp;Shuting Pan ,&nbsp;Guangyan Cai ,&nbsp;Xiangmei Chen ,&nbsp;Shuting Pan","doi":"10.1016/j.ekir.2025.01.027","DOIUrl":"10.1016/j.ekir.2025.01.027","url":null,"abstract":"<div><h3>Introduction</h3><div>Different starting doses of roxadustat are used for treating anemia in chronic kidney disease (CKD). We tested the noninferiority of weight-based lower starting dose compared with standard starting dose roxadustat for anemia in stage 3 to 5 CKD without dialysis.</div></div><div><h3>Methods</h3><div>Patients were randomized (1:1) and stratified by CKD stage to receive weight-based standard (&lt; 60 kg: 70 mg 3 times per week [TIW]; ≥ 60 kg: 100 mg TIW) or 1-step-lower (&lt; 60 kg: 50 mg TIW; ≥ 60 kg: 70 mg TIW) roxadustat starting dose for 16 weeks. The primary endpoint was mean hemoglobin change from baseline over weeks 12 to 16. The secondary endpoints included the proportion achieving hemoglobin 100 to 120 g/l, hemoglobin variability, and rescue therapy.</div></div><div><h3>Results</h3><div>Overall, 254 patients were randomized. The mean (SD) baseline hemoglobin was 89.88 (6.90) g/l. Most patients had stage 4 (39.0%) or stage 5 (40.2%) CKD. Mean hemoglobin increased from baseline at weeks 12 to 16 (lower: 21.57 g/l; standard: 26.35 g/l), but noninferiority was not met. A comparable proportion achieved hemoglobin of 100 to 120 g/l (lower: 46.0%; standard: 47.2%). The hemoglobin increase was comparable in CKD stage 3 to 4, but less with the lower dose in CKD stage 5 (17.28 vs. 26.71 g/l). The lower dose exhibited a lower hemoglobin rate of change (lower: 2.917; standard: 3.376) and less drug exposure. Drug-related adverse event rates were comparable.</div></div><div><h3>Conclusion</h3><div>The proportion of patients who achieved the hemoglobin target was comparable between the doses. The lower starting dose had less hemoglobin fluctuation and is recommended for stage 3 to 4 CKD.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1050-1062"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Exosomal mRNA Urine Test for Detection and Risk Stratification of Human Kidney Transplant Rejection","authors":"Rania El Fekih ,&nbsp;Kurt Franzen ,&nbsp;James Hurley ,&nbsp;Brian C. Haynes ,&nbsp;Tamara Merhej ,&nbsp;Areej Alghamdi ,&nbsp;Elliot Hallmark ,&nbsp;Shuran Xing ,&nbsp;Sonia Kumar ,&nbsp;John Choi ,&nbsp;Zhabiz Solhjou ,&nbsp;Christa Deban ,&nbsp;Anis Saad ,&nbsp;Ahmad Halawi ,&nbsp;Nour Younis ,&nbsp;Katherine Cashman ,&nbsp;Maribel Dagher ,&nbsp;Siawosh K. Eskandari ,&nbsp;Soltan Al Chaar ,&nbsp;Helmut Rennke ,&nbsp;Jamil R. Azzi","doi":"10.1016/j.ekir.2025.01.036","DOIUrl":"10.1016/j.ekir.2025.01.036","url":null,"abstract":"<div><h3>Introduction</h3><div>We recently discovered 2 urinary exosomal mRNA signatures to identify and differentiate T-cell–mediated rejection (TCMR) from antibody-mediated rejection (ABMR) in kidney transplant recipients. Here, we developed Exosome Transplant Rejection Urine (ExoTRU), a urinetest based on a 4-gene signature from the previous discovery cohort, showed its clinical utility in a new cohort of kidney transplant recipients undergoing clinically indicated biopsies, and validated it through a separate laboratory in an independent-cohort of patients.</div></div><div><h3>Methods</h3><div>A workflow suited for clinical laboratories was developed, allowing for smaller urine volumes and widely standardized qPCR instrumentation. A total of 226 urine samples from 214 patients were paired with clinically indicated biopsies. Urinary exosomal mRNAs levels were evaluated for previously defined targets.</div></div><div><h3>Results</h3><div>Four mRNAs (IL32, B2M, CXCL11, and PGK1) performed well in distinguishing biopsies with rejection or significant inflammation from those without inflammation, achieving 94% sensitivity, 62% positive predictive value, and 52% specificity. Patients who tested positive by the signature but negative by biopsy were nearly twice as likely to experience adverse outcomes in the 5-year follow-up period, including subsequent rejection, thereby showing the limitations of kidney biopsies and the prognostic potential of molecular signatures. The evaluation of an independent validation cohort showed similar performance, achieving an area under the curve (AUC) of 0.838. Another 6-gene signature distinguished TCMR from ABMR, with an AUC of 0.756.</div></div><div><h3>Conclusion</h3><div>Exosomal mRNA gene signatures identified patients with different stages and classes of rejection, including early stage and significant inflammation, enabling improved decision-making and patient management and reducing unnecessary biopsies by 45%. This represents a potential tool for risk stratification based on poor outcomes in patients with positive signatures.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1131-1142"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of ADPKD in Pregnancy","authors":"Ruth E. Campbell ,&nbsp;Charles L. Edelstein ,&nbsp;Michel Chonchol","doi":"10.1016/j.ekir.2024.12.035","DOIUrl":"10.1016/j.ekir.2024.12.035","url":null,"abstract":"<div><div>Autosomal dominant polycystic kidney disease (ADPKD) is a systemic disorder that often affects patients in their third to fifth decades of life and is characterized by kidney cysts, chronic kidney disease (CKD), hypertension, and hepatic cysts. The development of clinical symptoms often coincides with childbearing years. Consequently, there are several considerations regarding pregnant patients with ADPKD. In this review, we detail the effects and management of ADPKD in the peripartum period and discuss family planning options, including assisted reproductive techniques (ART) and preimplantation genetic testing.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1011-1019"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy","authors":"Fernando Caravaca-Fontán ,&nbsp;Remedios Toledo-Rojas ,&nbsp;Ana Huerta ,&nbsp;José Luis Pérez-Canga ,&nbsp;Patricia Martínez-Miguel ,&nbsp;Rosa Miquel ,&nbsp;Iara Da Silva ,&nbsp;Úrsula Verdalles ,&nbsp;Macarena Albornoz ,&nbsp;Carmen Mercedes Durán López ,&nbsp;Carmen Mon ,&nbsp;Gema Fernández-Juárez ,&nbsp;Manuel Praga","doi":"10.1016/j.ekir.2025.01.024","DOIUrl":"10.1016/j.ekir.2025.01.024","url":null,"abstract":"<div><h3>Introduction</h3><div>C3 glomerulopathy (C3G) and primary immune complex–mediated membranoproliferative glomerulonephritis (IC-MPGN) are rare diseases that share a similar pathogenesis; however, the prognostic significance of proteinuria reduction remains poorly characterized. This study compared the outcomes in C3G and IC-MPGN and assessed the impact of changes in proteinuria on kidney prognosis.</div></div><div><h3>Methods</h3><div>This retrospective, longitudinal, multicenter study used joint linear mixed-effects models to assess proteinuria trajectories, and Cox regression to evaluate their association with kidney failure. In addition, time-averaged proteinuria (TA-P) was calculated to determine its impact on kidney prognosis.</div></div><div><h3>Results</h3><div>The study included 149 patients: 98 with C3G (66%) and 51 with IC-MPGN (34%) with a median age of 35 (interquartile range [IQR]: 22–53) years. During a median follow-up of 65 (IQR: 32–114) months, 44 patients (30%) progressed to kidney failure without differences across C3G or IC-MPGN. A strong association was observed between longitudinal increase in proteinuria and the risk of kidney failure. In addition, a ≥ 50% proteinuria reduction over time was associated with a lower risk of kidney failure (hazard ratio [HR]: 0.61; 95% confidence interval [CI]: 0.46–0.75, <em>P</em> &lt; 0.001). Results were consistent in both C3G and IC-MPGN, and in those with baseline estimated glomerular filtration rate (eGFR) ≥ 30 ml/min per 1.73 m² and proteinuria ≥ 1 g/d. A ≥30% proteinuria reduction at 6 months or a ≥50% proteinuria reduction at 12 months were associated with a slower eGFR decline. Patients were categorized into 4 subgroups based on TA-P levels, with TA-P values &lt; 1 g/d indicating better kidney outcomes.</div></div><div><h3>Conclusion</h3><div>Proteinuria reduction was associated with improved kidney outcomes and slower eGFR decline in both C3G and IC-MPGN.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 4","pages":"Pages 1223-1236"},"PeriodicalIF":5.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating Number of Nephrons in Living Pediatric Patients Using Nephrectomy Specimens","authors":"Haruhide Sakaguchi ,&nbsp;Daishi Hirano ,&nbsp;Yuhei Kawakami ,&nbsp;Ai Tokunaga ,&nbsp;Naoto Nishizaki ,&nbsp;Amane Endo ,&nbsp;Hiroki Miyano ,&nbsp;Yuki Yuza ,&nbsp;Saeko Hatanaka ,&nbsp;Takaya Sasaki ,&nbsp;Go Kanzaki ,&nbsp;Nobuo Tsuboi ,&nbsp;Kimihiko Oishi","doi":"10.1016/j.ekir.2024.12.027","DOIUrl":"10.1016/j.ekir.2024.12.027","url":null,"abstract":"<div><h3>Introduction</h3><div>The number of nephrons is a critical determinant of renal health, because chronic kidney disease often results from a reduction in functional nephrons. Variability in the number of nephrons is influenced by genetic, racial, prenatal, and postnatal factors. Estimating the number of nephrons is crucial for establishing a baseline, before the onset of age-related nephron loss. This study aimed to estimate number of nephrons in pediatric patients by using imaging and histological techniques.</div></div><div><h3>Methods</h3><div>This retrospective study included pediatric patients with renal tumors, who are undergoing nephrectomy and contrast-enhanced computed tomography (CT) between January 2010 and January 2021. Postsurgical renal tissue specimens were fixed, stained, and scanned into high-resolution digital images. Nonsclerotic glomerular density was calculated using stereological methods, whereas renal cortical volume was measured using ITK-SNAP software on CT images. The total number of nephrons was estimated based on cortical volume and glomerular density. Statistical analyses were conducted to identify the correlations between the number of nephrons and clinical factors.</div></div><div><h3>Results</h3><div>Twenty-one children met the inclusion criteria. The cohort comprised 13 boys (61.9%) and 8 girls (38.1%) with a median age at nephrectomy of 2.5 years. The median number of nephrons per kidney was 925,000 (interquartile range [IQR]: 845,000–1,020,000). Higher number of nephrons was significantly correlated with older age at nephrectomy (<em>ρ</em> = 0.47, <em>P</em> = 0.036) and larger body surface area (BSA; <em>ρ</em> = 0.45, <em>P</em> = 0.034).</div></div><div><h3>Conclusion</h3><div>This study offers new insights into pediatric nephron endowment, emphasizing the importance of early nephron assessment for predicting long-term renal outcomes.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 3","pages":"Pages 772-779"},"PeriodicalIF":5.7,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143550808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}